Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports-Reference-Cited by-同舟云学术

Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports

Published:2011-02-28 Issue:5 Volume:102 Page:1032-1037
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:

Author:

Shukuya Takehito,Takahashi Toshiaki,Kaira Rieko,Ono Akira,Nakamura Yukiko,Tsuya Asuka,Kenmotsu Hirotsugu,Naito Tateaki,Kaira Kyoichi,Murakami Haruyasu,Endo Masahiro,Takahashi Kazuhisa,Yamamoto Nobuyuki

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2011.01887.x/fullpdf

Reference39 articles.

1. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

3. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions;Pao;J Clin Oncol,2005

4. Biological and clinical implications of EGFR mutations in lung cancer;Mitsudomi;Int J Clin Oncol,2006

5. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer;Mitsudomi;Cancer Sci,2007

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ensartinib in the treatment of anaplastic lymphoma kinase‐positive locally advanced or metastatic patients with lung squamous or adenosquamous carcinoma: A real‐world, retrospective study;Asia-Pacific Journal of Clinical Oncology;2024-06-19

2. Review on EGFR-ERK1/2 signaling cascade: implications on cell proliferation in health and disease;Egyptian Pharmaceutical Journal;2023-10

3. The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity;Cancer Discovery;2023-07-20

4. A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non–Small Cell Lung Cancer Study: (NEJ048A/NEXUS);Clinical Lung Cancer;2023-06

5. Two Cases of Squamous Cell Lung Carcinoma with EGFR Mutations Presenting Poor Outcomes After Osimertinib Treatment;Haigan;2023-02-20